RxDoctor Payments Data

Paige Oliver, OD

Optometrist · Waterville, MENPI 1912566290

Payments from drug & device makers

What this record shows

This record is dominated by other: $1,692 of the $2,108 with a category attached, or 80.3%. Carl Zeiss Meditec USA, Inc. accounts for 80.3% of it on its own, with 8 other manufacturers making up the rest. Among optometrist clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,108in general payments, 2019–2025

Across 15 payments — averaging $140.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec USA, Inc.$2K
  • AbbVie$215
  • Alcon$71
  • Bausch & Lomb Americas Inc.$39
  • Oyster Point Pharma, Inc.$27
  • Rxsight Inc$19
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$41620%
  • Other$1,69280%

General payments by program year

22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,108 in reported general payments places this provider in the 90th percentile of 224 optometrist providers in Maine.

See all optometrist providers in Maine

Medicare billing

Part B allowed, 2024
$74,285
Medicare patients
389
Services billed
942

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine17$25,689
LumiganBimatoprost21$12,531
TobradexTobramycin/Dexamethasone11$2,877
Latanoprost189$2,475
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$1,426
Timolol Maleate105$971
Tobramycin-DexamethasoneTobramycin/Dexamethasone12$482
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat17$386
MoxifloxacinMoxifloxacin Hcl12$264
Dorzolamide Hcl29$258
Brimonidine Tartrate12$239
ErythromycinErythromycin Base18$164
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha20$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$215$38,22038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 224 optometrist providers in Maine.

Other optometrist in Waterville

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →